Health
Novo Sees Ozempic Boom Prompting Another Sales Surge
- Danish drugmaker sees revenue growing 16% to 24% this year
- Novo expects more periodic supply constraints for blockbusters
This article is for subscribers only.
Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes medicine Ozempic and obesity treatment Wegovy.
Revenue will likely grow by 16% to 24% at constant exchange rates, the company said Wednesday. That compares with 26% for last year. The shares climbed as much as 6.3% in Copenhagen trading after the forecast and better-than-expected results.